Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single center, open-label, accelerated titration, dose-escalating, phase Ι study to evaluate the safety and tolerability of IT injection GX-051, stem cell based gene therapeutics in patients with very advanced head and neck cancer

Trial Profile

A single center, open-label, accelerated titration, dose-escalating, phase Ι study to evaluate the safety and tolerability of IT injection GX-051, stem cell based gene therapeutics in patients with very advanced head and neck cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GX 051 (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors Genexine
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 05 Apr 2015 Planned End Date changed from 1 Feb 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top